Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed

Hidetoshi Hayashi, Isamu Okamoto, Yasuko Ichikawa, Masaki Miyazaki, Hiroshige Yoshioka, Kei Kunimasa, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Combination chemotherapy with cisplatin and pemetrexed is the most active first-line regimen for malignant pleural mesothelioma (MPM). However, no drugs have been approved for second-line treatment of MPM, with effective regimens remaining to be identified for patients in relapse. We have now evaluated the combination of cisplatin and pemetrexed for retreatment of patients with recurrent MPM. Four men with MPM, all of whom received initial treatment with cisplatin and pemetrexed, underwent retreatment with this drug combination. Two of the patients achieved an objective response to the first-line chemotherapy with no evidence of disease progression for 6.4 or 11.4 months, respectively. The other two patients had stable disease with a duration of 7.8 or 5.0 months, respectively. The two patients who showed an objective response to first-line chemotherapy showed a partial response to retreatment, with a time to progression of 5.0 or 8.2 months, whereas the other two patients had progressive disease with a time to progression of 1.0 or 1.4 months, respectively. Retreatment with cisplatin plus pemetrexed was generally well tolerated. Retreatment with cisplatin and pemetrexed is a potential therapeutic option for certain patients with recurrent epithelioid MPM, possibly including those who show tumor regression with a time to progression of 6 months or more after the initial chemotherapy. Further studies are warranted to evaluate the efficacy of such retreatment and to clarify the criteria for patient selection.

Original languageEnglish
Pages (from-to)497-499
Number of pages3
JournalInternational Journal of Clinical Oncology
Volume15
Issue number5
DOIs
Publication statusPublished - Oct 1 2010

Fingerprint

Pemetrexed
Retreatment
Cisplatin
Drug Therapy
Drug Combinations
Malignant Mesothelioma
Combination Drug Therapy
Patient Selection
Disease Progression
Therapeutics
Recurrence

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Cite this

Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed. / Hayashi, Hidetoshi; Okamoto, Isamu; Ichikawa, Yasuko; Miyazaki, Masaki; Yoshioka, Hiroshige; Kunimasa, Kei; Nakagawa, Kazuhiko.

In: International Journal of Clinical Oncology, Vol. 15, No. 5, 01.10.2010, p. 497-499.

Research output: Contribution to journalArticle

Hayashi, Hidetoshi ; Okamoto, Isamu ; Ichikawa, Yasuko ; Miyazaki, Masaki ; Yoshioka, Hiroshige ; Kunimasa, Kei ; Nakagawa, Kazuhiko. / Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed. In: International Journal of Clinical Oncology. 2010 ; Vol. 15, No. 5. pp. 497-499.
@article{15f0b816552d4330b473772b5cf479c6,
title = "Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed",
abstract = "Combination chemotherapy with cisplatin and pemetrexed is the most active first-line regimen for malignant pleural mesothelioma (MPM). However, no drugs have been approved for second-line treatment of MPM, with effective regimens remaining to be identified for patients in relapse. We have now evaluated the combination of cisplatin and pemetrexed for retreatment of patients with recurrent MPM. Four men with MPM, all of whom received initial treatment with cisplatin and pemetrexed, underwent retreatment with this drug combination. Two of the patients achieved an objective response to the first-line chemotherapy with no evidence of disease progression for 6.4 or 11.4 months, respectively. The other two patients had stable disease with a duration of 7.8 or 5.0 months, respectively. The two patients who showed an objective response to first-line chemotherapy showed a partial response to retreatment, with a time to progression of 5.0 or 8.2 months, whereas the other two patients had progressive disease with a time to progression of 1.0 or 1.4 months, respectively. Retreatment with cisplatin plus pemetrexed was generally well tolerated. Retreatment with cisplatin and pemetrexed is a potential therapeutic option for certain patients with recurrent epithelioid MPM, possibly including those who show tumor regression with a time to progression of 6 months or more after the initial chemotherapy. Further studies are warranted to evaluate the efficacy of such retreatment and to clarify the criteria for patient selection.",
author = "Hidetoshi Hayashi and Isamu Okamoto and Yasuko Ichikawa and Masaki Miyazaki and Hiroshige Yoshioka and Kei Kunimasa and Kazuhiko Nakagawa",
year = "2010",
month = "10",
day = "1",
doi = "10.1007/s10147-010-0064-7",
language = "English",
volume = "15",
pages = "497--499",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed

AU - Hayashi, Hidetoshi

AU - Okamoto, Isamu

AU - Ichikawa, Yasuko

AU - Miyazaki, Masaki

AU - Yoshioka, Hiroshige

AU - Kunimasa, Kei

AU - Nakagawa, Kazuhiko

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Combination chemotherapy with cisplatin and pemetrexed is the most active first-line regimen for malignant pleural mesothelioma (MPM). However, no drugs have been approved for second-line treatment of MPM, with effective regimens remaining to be identified for patients in relapse. We have now evaluated the combination of cisplatin and pemetrexed for retreatment of patients with recurrent MPM. Four men with MPM, all of whom received initial treatment with cisplatin and pemetrexed, underwent retreatment with this drug combination. Two of the patients achieved an objective response to the first-line chemotherapy with no evidence of disease progression for 6.4 or 11.4 months, respectively. The other two patients had stable disease with a duration of 7.8 or 5.0 months, respectively. The two patients who showed an objective response to first-line chemotherapy showed a partial response to retreatment, with a time to progression of 5.0 or 8.2 months, whereas the other two patients had progressive disease with a time to progression of 1.0 or 1.4 months, respectively. Retreatment with cisplatin plus pemetrexed was generally well tolerated. Retreatment with cisplatin and pemetrexed is a potential therapeutic option for certain patients with recurrent epithelioid MPM, possibly including those who show tumor regression with a time to progression of 6 months or more after the initial chemotherapy. Further studies are warranted to evaluate the efficacy of such retreatment and to clarify the criteria for patient selection.

AB - Combination chemotherapy with cisplatin and pemetrexed is the most active first-line regimen for malignant pleural mesothelioma (MPM). However, no drugs have been approved for second-line treatment of MPM, with effective regimens remaining to be identified for patients in relapse. We have now evaluated the combination of cisplatin and pemetrexed for retreatment of patients with recurrent MPM. Four men with MPM, all of whom received initial treatment with cisplatin and pemetrexed, underwent retreatment with this drug combination. Two of the patients achieved an objective response to the first-line chemotherapy with no evidence of disease progression for 6.4 or 11.4 months, respectively. The other two patients had stable disease with a duration of 7.8 or 5.0 months, respectively. The two patients who showed an objective response to first-line chemotherapy showed a partial response to retreatment, with a time to progression of 5.0 or 8.2 months, whereas the other two patients had progressive disease with a time to progression of 1.0 or 1.4 months, respectively. Retreatment with cisplatin plus pemetrexed was generally well tolerated. Retreatment with cisplatin and pemetrexed is a potential therapeutic option for certain patients with recurrent epithelioid MPM, possibly including those who show tumor regression with a time to progression of 6 months or more after the initial chemotherapy. Further studies are warranted to evaluate the efficacy of such retreatment and to clarify the criteria for patient selection.

UR - http://www.scopus.com/inward/record.url?scp=78149361192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149361192&partnerID=8YFLogxK

U2 - 10.1007/s10147-010-0064-7

DO - 10.1007/s10147-010-0064-7

M3 - Article

C2 - 20224880

AN - SCOPUS:78149361192

VL - 15

SP - 497

EP - 499

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 5

ER -